13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02587806 (ClinicalTrials.gov) | February 2015 | 26/10/2015 | A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | Multiple Sclerosis, Relapsing-Remitting | Biological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapy | Novo Cellular Medicine Institute LLP | NULL | Recruiting | 18 Years | 60 Years | Both | 69 | Phase 1/Phase 2 | India;Trinidad and Tobago |
| 2 | NCT02418351 (ClinicalTrials.gov) | February 2015 | 8/4/2015 | A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS | Multiple Sclerosis, Relapsing-Remitting | Biological: Autologous Bone Marrow-Derived Mononuclear Stem Cells;Other: Liberation therapy | Genesis Limited | NULL | Terminated | 18 Years | 60 Years | Both | 69 | Phase 1/Phase 2 | India;Trinidad and Tobago |